AmerisourceBergen Corporation announced unaudited consolidated earnings results for the fiscal quarter ended December 31, 2012. Revenue was $21.5 billion in the first quarter of fiscal 2013, a 5.7% increase over $20.31 billion for the same quarter in the previous fiscal year, driven by a 4.8% increase in AmerisourceBergen Drug Corporation (ABDC) revenue, and a 9.6% increase in AmerisourceBergen Specialty Group (ABSG) revenue. In the fiscal 2013 first quarter, operating income increased 2.1% to $287.3 million over $281.42 million for the same quarter in the previous fiscal year, due to the increase in gross profit, which was largely offset by the increase in operating expenses.

Diluted earnings per share from continuing operations were up 13.1% to $0.69 in the first quarter of fiscal 2013 compared to $0.61 in the previous fiscal year's first quarter. Earnings per share growth exceeded the 1.4% growth in income from continuing operations due to the 10.3% reduction in diluted average shares outstanding. The company reported that in its fiscal year 2013 first quarter, ended December 31, 2012, diluted earnings per share was $0.71, a 14.5% increase compared to $0.62 in the previous fiscal year's first quarter.

Income from continuing operations before income taxes was $268,584,000 against $258,844,000 for the same period of last year. Income from continuing operations was $162,225,000 against $159,957,000 for the same period of last year. Net income was $168,611,000 against $162,116,000 for the same period of last year.

Net cash used in operating activities was $241,707,000 against net cash provided by operating activities of $431,703,000 for the same period of last year. Capital expenditures were $56,543,000 against $45,531,000 for the same period of last year.